HCMV neutralizing antibodies

Novel monoclonal antibodies targeting HCMV trimer and pentamer complexes with defined CDR sequences provide enhanced neutralizing activity against HCMV, addressing the limitations of current treatments by effectively reducing infections in multiple cell types.

JP2026523251APending Publication Date: 2026-07-13UNIVERSITATE ZU COLOGNE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025576540
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-26
Filing Date
2024-06-26
Publication Date
2026-07-13

AI Technical Summary

Technical Problem

Current treatments for human cytomegalovirus (HCMV) infection, including vaccines and antiviral drugs, are limited by insufficient efficacy, emergence of drug-resistant strains, and side effects, necessitating improved antibody-based therapies that can neutralize HCMV infections in various cell types.

Method used

Development of novel monoclonal antibodies targeting novel epitopes of HCMV trimer and pentamer complexes, specifically designed with defined CDR sequences, to effectively neutralize HCMV infections in epithelial, endothelial, and fibroblast cells.

Benefits of technology

The novel antibodies demonstrate potent neutralizing activity with low IC50 values, effectively reducing HCMV infection in target cells, including IC50 values of 150 ng/ml or less in fibroblasts, 50 ng/ml or less in epithelial cells, and 40 ng/ml or less in endothelial cells, surpassing the efficacy of existing antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026523251000007
    Figure 2026523251000007
  • Figure 2026523251000008
    Figure 2026523251000008
  • Figure 2026523251000009
    Figure 2026523251000009
Patent Text Reader

Abstract

The present invention relates to antibodies or antigen-binding fragments thereof against human cytomegalovirus (HCMV), pharmaceutical compositions comprising such antibodies or antigen-binding fragments, kits comprising such antibodies or antigen-binding fragments, and antibodies or antigen-binding fragments thereof, pharmaceutical compositions and kits for use as pharmaceuticals and in the treatment or prevention of infection by human cytomegalovirus. The present invention further relates to nucleic acids encoding such antibodies or antigen-binding fragments as described above, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for producing such antibodies or antigen-binding fragments.
Need to check novelty before this filing date? Find Prior Art